CLAIMS

1. Use of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide for producing a pharmaceutical composition for treating a tumor, wherein (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide is to be administered in combination with lenvatinib or a pharmaceutically acceptable salt thereof.

2. Use of lenvatinib or a pharmaceutically acceptable salt thereof for producing a pharmaceutical composition for treating a tumor, wherein lenvatinib or a pharmaceutically acceptable salt thereof is to be administered in combination with (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.

3. Use according to claim 1 or 2, wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.

4. Use according to any one of claims 1 to 3, further comprising an excipient.

5. Use according to any one of claims 1 to 4, wherein the lenvatinib or the pharmaceutically acceptable salt thereof, and the (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide are to be administered simultaneously, separately, continuously, or at time intervals.

6. Use according to any one of claims 1 to 5, wherein the tumor is breast cancer, thyroid cancer, hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, head and neck cancer, endometrial cancer or melanoma.

7. Use according to claim 6, wherein the tumor is breast cancer.

8. Use according to claim 6, wherein the tumor is thyroid cancer.

9. Use according to claim 8, wherein the thyroid cancer is anaplastic thyroid cancer.

10. Use according to claim 6, wherein the tumor is hepatocellular carcinoma.

11. Use according to claim 6, wherein the tumor is colorectal cancer.

12. Use according to claim 6, wherein the tumor is renal cell carcinoma.

13. Use according to claim 6, wherein the tumor is head and neck cancer.

14. Use according to claim 6, wherein the tumor is endometrial cancer.

15. Use according to claim 6, wherein the tumor is melanoma.

16. A pharmaceutical composition for treating a tumor, comprising lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.